Desk›Healthcare› Eris Lifesciences Ltd
Eris Lifesciences Ltd
BSE 540596 · NSE ERIS · ISIN INE406M01024 · Group A · Active
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
₹1,317.10
+0.42%
BSE close, 28 August 2026
₹18,252.81 cr
13.9 cr shares · Small cap
₹6,754.36 cr
as published
94.9× · 7.08×
EPS ₹13.88 · BV ₹186.03
1,821.74 / 244.05
₹ cr, as filed
31
6 selected · 19%
Reg 30
Sch. III Part A
Price 52-week, BSE
| Against 52-week high | -27.3% |
|---|---|
| Against 52-week low | +6.4% |
| Day change | +0.42% |
| Size band | Small cap |
| Index membership | NIFTY 500 |
Valuation as published by BSE
| Earnings per share | ₹13.88 |
|---|---|
| Price / earnings | 94.89× |
| Price / book | 7.08× |
| Book value — derived, price ÷ P/B | ₹186.03 |
| Return on equity | 7.46% |
| Operating margin | 32.95% |
| Net margin | 10.88% |
Consistency check
- P/B ÷ P/E, which must equal ROE
- 7.46%
- ROE as published
- 7.46%
Results ₹ crore, as filed
RevenueNet profit one scale across all three periods, ₹ crore
| Period | Revenue ₹cr | Net profit ₹cr | EPS ₹ | OPM | NPM |
|---|---|---|---|---|---|
| Jun-26 · Q | 443.99 | 48.30 | 3.49 | 32.95% | 10.88% |
| Mar-26 · Q | 277.31 | -8.60 | -0.63 | 17.58% | -3.10% |
| FY25-26 | 1,821.74 | 244.05 | 17.86 | 38.20% | 13.40% |
Quarter on quarter
- Revenue, quarter on quarter
- +60.1%
- Net profit, quarter on quarter
- +661.6%
- Operating margin, quarter on quarter
- +1,537 bps
Disclosure profile 31 filings in the window
| Tag | Filings |
|---|---|
| Selected | |
| Resignation | 2 |
| Board Outcome | 1 |
| Concall Transcript | 1 |
| Investor Presentation | 1 |
| Results | 1 |
| Selected sub-total | 6 |
| Procedural | |
| Analyst / Investor Meet | 7 |
| AGM / EGM | 4 |
| General | 4 |
| Newspaper Publication | 2 |
| Allotment | 1 |
| Annual Report | 1 |
| BRSR | 1 |
| Board Meeting | 1 |
| Compliance Certificate | 1 |
| ESOP Allotment | 1 |
| Outcome | 1 |
| Trading Window | 1 |
| Procedural sub-total | 25 |
| Total | 31 |
Disclosure regime
LODR Reg 30
Read with Schedule III Part A. An equity filer in BSE Group A, so the Regulation 30 disclosure framework and the Schedule III event list both apply.
Filing rhythm · 93 trading days
31 filings · 6 selected · busiest 2026-07-29 and 2026-09-02
Filing rhythm · the twelve most recent
2026-09-072026-10-07
SelectedProcedural
Filings
31 in the window · 5 earlier on record
-
7 October 2026 ·
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
As Attached
Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 View filing →
-
5 October 2026 ·
-
28 September 2026 ·
Closure of Trading Window
As Attached
Insider Trading / SAST / Closure of Trading Window View filing →
-
25 September 2026 ·
-
25 September 2026 ·
Shareholder Meeting / Postal Ballot-Outcome of AGM
Proceedings of 20th AGM held on September 25 2026
AGM/EGM / AGM View filing →
-
25 September 2026 ·
Shareholder Meeting / Postal Ballot-Outcome of AGM
Proceedings of 29th Annual General Meeting of the Company held on 25th September 2026.
AGM/EGM / AGM View filing →
-
22 September 2026 ·
-
21 September 2026 ·
Appointment Of Mr. Akhil Awasthi As An Additional Director (Non-Executive, Independent) Of The Company
as attached
Company Update / General View filing →
-
11 September 2026 ·
-
10 September 2026 ·
Rumour Verification - Regulation 30(11)
Eris Lifesciences Limited has informed the exchange about Rumor verification-Regulation 30 (11)
Company Update / General View filing →
-
9 September 2026 ·
Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015, - Availing Term Loan From Axis Bank
As attached
Company Update / General View filing →
-
7 September 2026 ·
Analyst / Investor Meet - Intimation
As Attached
Company Update / Analyst / Investor Meet View filing →
-
3 September 2026 ·
-
2 September 2026 ·
-
2 September 2026 ·
Business Responsibility and Sustainability Reporting (BRSR)
as attached
Others / Business Responsibility and Sustainability Reporting (BRSR) View filing →
-
2 September 2026 ·
-
2 September 2026 ·
Annual General Meeting Of The Company Scheduled On September 25, 2026
as attached
AGM/EGM / AGM View filing →
-
31 August 2026 ·
Board Meeting Outcome for Outcome For Board Meeting
As Attached
Others / Outcome without intimation View filing →
-
24 August 2026 ·
Analyst / Investor Meet - Intimation
As Attached
Company Update / Analyst / Investor Meet View filing →
-
12 August 2026 ·
Analyst / Investor Meet - Intimation
as attached
Company Update / Analyst / Investor Meet View filing →
-
10 August 2026 ·
Analyst / Investor Meet - Intimation
As Attached
Company Update / Analyst / Investor Meet View filing →
-
6 August 2026 ·
Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015, - Availing Working Capital Term Loan From Axis Bank
as attached
Company Update / General View filing →
-
4 August 2026 ·
-
30 July 2026 ·
Analyst / Investor Meet - Intimation
As Attached
Company Update / Analyst / Investor Meet View filing →
-
30 July 2026 ·
-
29 July 2026 ·
Analyst / Investor Meet - Outcome
As Attached
Company Update / Analyst / Investor Meet View filing →
-
29 July 2026 ·
-
29 July 2026 ·
Financial Results For The Quarter Ended June 30, 2026
as attached
Result / Financial Results View filing →
-
29 July 2026 ·
Board Meeting Outcome for Outcome Of Board Meeting
as attached
Board Meeting / Outcome of Board Meeting View filing →
-
23 July 2026 ·
Analyst / Investor Meet - Intimation
As Attached
Company Update / Analyst / Investor Meet View filing →
-
23 July 2026 ·
Board Meeting Intimation for Consideration And Approval Of The Financial Results For The Period Ended June 30, 2026
Eris Lifesciences Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/07/2026 ,inter alia, to consider and approve the financial results for ....
Board Meeting / Board Meeting View filing →
RSS feed for Eris Lifesciences Ltd · the 50 most recent filings